2-trifluoromethoxy-5-formyl-phenyl boronic acid | 459810-97-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-trifluoromethoxy-5-formyl-phenyl boronic acid
• 英文别名: 3-formyl-6-trifluoromethoxy-1-phenyl boronic acid；5-Formyl-2-(trifluoromethoxy)benzeneboronic acid；[5-formyl-2-(trifluoromethoxy)phenyl]boronic acid
• CAS: 459810-97-0
• 化学式: C₈H₆BF₃O₄
• 分子量: 233.939
• InChiKey: YIQZPNQAVZJFIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.08
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-trifluoromethoxy-5-formyl-phenyl boronic acid 在 四(三苯基膦)钯 N,N-二甲基丙烯基脲 、 正丁基锂 、 potassium carbonate 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 8.0h， 生成 (E)-3-[3-(4-ethyl-2,7-dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-4-triflouromethoxy-phenyl]-acrylic acid
  参考文献：
  名称：

  RXR–LXR heterodimer modulators for the potential treatment of dyslipidemia

  摘要：

  A number of RXR agonists were synthesized and screened in functional assays. The synthesis and tile structure-activity relationship (SAR) within the series of compounds will be presented. Some in vivo data in rodent models for dyslipidemia and diabetes will also be presented. (c) 2007 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2007.01.047

文献信息

• Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
  申请人：——

  公开号：US20030083357A1

  公开（公告）日：2003-05-01

  The present invention relates to compounds of Formula (I) which may be useful in the treatment of diseases, such as, metabolic disorders, dyslipidemia and/or hyperchloesterolemia: 1

  本发明涉及Formula (I)的化合物，可能在治疗疾病，如代谢紊乱、血脂异常和/或高胆固醇血症方面有用：
• N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
  申请人：——

  公开号：US20030144329A1

  公开（公告）日：2003-07-31

  The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia: 1

  本发明涉及某些化合物的公式（I），这些化合物可用于治疗疾病，如癌症、代谢紊乱、2型糖尿病、血脂异常和/或高胆固醇血症。
• Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
  申请人：Lagu Bharat

  公开号：US20070078129A1

  公开（公告）日：2007-04-05

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating RXR mediated disorders. More particularly, the compounds of the present invention are RXR agonists useful for treating RXR mediated disorders.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物以及用于治疗RXR介导的疾病。更具体地说，本发明的化合物是RXR激动剂，可用于治疗RXR介导的疾病。
• DIHYDRO-[1H]-QUINOLIN-2-ONE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES
  申请人：Lagu Bharat

  公开号：US20070078160A1

  公开（公告）日：2007-04-05

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating RXR mediated disorders. More particularly, the compounds of the present invention are RXR agonists useful for treating RXR mediated disorders.

  本发明涉及式（I）的化合物，制备这些化合物的方法，组合物，中间体和衍生物，以及治疗RXR介导的疾病。更具体地说，本发明的化合物是RXR激动剂，可用于治疗RXR介导的疾病。
• RXR activating molecules
  申请人：——

  公开号：US20030105333A1

  公开（公告）日：2003-06-05

  Disclosed are molecules that activate an RXR receptor, wherein the molecule comprises an RXR binding portion which binds the RXR receptor and comprises a side pocket contacting residue which contacts a side-pocket 1 of an RXR receptor.

  本发明涉及可以激活RXR受体的分子，其中所述分子包括与RXR受体结合的RXR结合部分，包括与RXR受体的侧袋1接触的侧袋接触残基。